Navigation Links
Regenesis Biomedical Announces Additions to Board of Directors
Date:8/22/2008

Strengthens breadth of experience and business expertise

SCOTTSDALE, Ariz., Aug. 22 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant(R) Wound Therapy System, announced today the addition of two members to its Board of Directors. The two new directors are Peter G. Savas, Chairman and CEO of Alseres Pharmaceuticals, and Charles "Chuck" S. Lunden, a principal with Bederson and Company.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008)

Peter Savas serves as Chairman and Chief Executive Officer of Alseres Pharmaceuticals. Prior to joining Alseres, Peter was Chairman and Chief Executive Officer of Aderis Pharmaceuticals, where he completed a $45 million private placement, strengthened the Board of Directors, Scientific Advisory Board and management team and rationalized the company's new product development partnerships. Peter holds his Bachelor of Arts degree in chemistry from Syracuse University.

Chuck Lunden is a Principal with Bederson and Company, certified public accountant consultants who provide financial and accounting services. He has comprehensive experience in corporate valuation and financial, tax and corporate management services. His designations include Certified Public Accountant, Accredited in Business Valuations, Certified Fraud Examiner, Certified Management Accountant, Chartered Life Underwriter, and Fellow of the Life Management Institute. Chuck holds a Bachelor of Science degree in economics from the University of Pennsylvania's Wharton School of Business. He is a member of the Board of Directors of HealthCare Data Diagnostics, a Medicare data analysis firm specializing in fraud detection. He is also a Member of the Board of Directors of the Spanish Health Ministries Inc.

"We are pleased to welcome these outstanding individuals to our team," said Virginia Rybski, Acting President of Regenesis. "Regenesis continues to demonstrate impressive revenue growth, and the perspectives of these individuals will contribute to our ongoing business plan execution."

About the Provant Wound Therapy System

Provant uses pulsed-radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative superficial soft tissues.

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

Contact: Regenesis Biomedical, Inc.

Scott Robey, Vice President Marketing

http://www.regenesisbiomedical.com 480-970-4970


'/>"/>
SOURCE Regenesis Biomedical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical
2. Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts
3. Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R)
4. Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
5. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
6. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
7. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
8. Roche and Response Biomedical Corporation Aim to Reduce Vein-to-Brain Time with New Point-of-Care Cardiac Tests
9. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
10. HIPAA Privacy Rule Impedes Biomedical Research
11. Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... 20, 2017 , ... Cybrexa Therapeutics , a start-up ... role of chief scientific officer. In this role, Dr. Paralkar will lead the ... CEO, Per Hellsund. , “I was impressed with Cybrexa’s revolutionary technology and excellent ...
(Date:9/20/2017)... MD (PRWEB) , ... September 20, 2017 , ... ... digital pathology, and Huron Digital Pathology , a provider of whole slide ... 2017 Pathology Visions conference . The workshop, entitled “Successfully Deploying a Best-in-Class Strategy ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... focused on molecular manufacturing and other transformative technologies, announced the winners for the ... and the other for Theory in nanotechnology/molecular manufacturing. , Established in 1993 and ...
(Date:9/19/2017)... ... September 19, 2017 , ... Participants of this ... high-performance fume hood. Along with the advantages and disadvantages of ductless, filtered fume ... hoods in the laboratory. , Attendees will learn from an industry expert about ...
Breaking Biology Technology:
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
Breaking Biology News(10 mins):